Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer HealthCare business

Ipsen is pleased to announce its strong 2021 financial performance with total-sales growth of 12.3% at CER1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%). We set our full-year 2022 guidance, excluding CHC, with total-sales growth greater than 2.0% at CER1 and a core operating margin greater than 35% of total sales. Our 2024 outlook, excluding CHC, with a total-sales 2020-24 CAGR2 has been updated to between 4% and 6% at constant currency and cumulative remaining firepower of €3.5bn by 2024, including the divestment of CHC.

Today’s announcement included the news that we are entering into exclusive negotiations with Mayoly Spindler to divest our Consumer HealthCare business. This is a major step forward in the execution of the strategic roadmap we presented in December 2020 towards building a more focused Ipsen, centering on Specialty Care.

CEO David Loew said, “The strong results in 2021 are aligned with our strategic intent, with improving levels of commercial execution reflecting in excellent performances from every major brand. As the replenishment of our pipeline gathered pace, it was an exciting year for business development and our key clinical programs. Furthermore, sharpening our focus on Specialty Care, I am pleased that we have entered into exclusive negotiations to divest our Consumer Healthcare business.”

We will continue to grow our business in 2022, and beyond, through our core and innovative brands while in addition, supporting growth through external innovation. Based on our strategy and our improved execution, we are pleased to update our mid-term outlook, underpinning the strength of Ipsen’s growth story built on our culture and an unrelenting focus on patients.”


You can find the full press release here.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022